利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.039 秒)

    Epha4 As Therapeutic Target Of Prc And Pdaca
    11.
    发明申请
    Epha4 As Therapeutic Target Of Prc And Pdaca 审中-公开
    Epha4作为Prc和Pda​​ca的治疗靶点

    公开(公告)号：US20070253954A1

    公开(公告)日：2007-11-01

    申请号：US10590801

    申请日：2005-02-18

    申请人： Yusuke Nakamura ,  Hidewaki Nakagawa ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Hidewaki Nakagawa ,  Shuichi Nakatsuru

    IPC分类号： A61K31/7088 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/63 ,  C12Q1/48 ,  C12Q1/68 ,  G01N33/00

    CPC分类号： G01N33/5011 ,  A61K39/0011 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/53 ,  C12Q1/6886 ,  C12Q1/6897 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/57434 ,  Y10T436/143333

    摘要： Objective methods for diagnosing a predisposition to developing prostate cancer (PRC) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of EphA4. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRC, methods of treating PRC. The invention also features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a siRNA of EPHA4. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example pancreatic cancer cell, particularly pancreatic ductal adenocarcinoma (PDACa).

    摘要翻译： 本文描述了诊断发展中的前列腺癌（PRC）倾向的客观方法。 在一个实施方案中，诊断方法涉及确定EphA4的表达水平。 本发明还提供筛选用于治疗PRC的治疗剂的方法，以及治疗PRC的方法。 本发明还具有通过使细胞与EPHA4的siRNA的组合物接触来抑制癌细胞生长的方法。 治疗癌症的方法也在本发明的范围内。 本发明还包括可用于所提供的方法的产品，包括核酸序列和载体以及包含它们的组合物。 本发明还提供了抑制肿瘤细胞的方法，例如胰腺癌细胞，特别是胰腺导管腺癌（PDACa）。

    PKIB and NAALADL2 for Target Genes of Prostate Cancer Therapy and Diagnosis
    13.
    发明申请
    PKIB and NAALADL2 for Target Genes of Prostate Cancer Therapy and Diagnosis 审中-公开
    PKIB和NAALADL2用于前列腺癌治疗和诊断的靶基因

    公开(公告)号：US20120022128A1

    公开(公告)日：2012-01-26

    申请号：US12674664

    申请日：2008-08-20

    申请人： Yusuke Nakamura ,  Hidewaki Nakagawa ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Hidewaki Nakagawa ,  Shuichi Nakatsuru

    IPC分类号： A61K31/713 ,  C12N15/63 ,  C12Q1/68 ,  A61P35/00 ,  C40B30/04 ,  C07K16/44 ,  C07K16/18 ,  G01N33/566 ,  C12N15/113 ,  G01N33/574

    CPC分类号： A61K31/70 ,  A61K48/00 ,  C07K14/47 ,  C12N15/113 ,  C12N2310/111 ,  C12N2310/14

    摘要： The invention features methods for detecting prostate cancer, especially hormone-refractory prostate cancer (HRPC) or castration-resistant prostate cancer (CRPC), by detecting over-expression of PKIB or NAALADL2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing prostate cancer including HRPC, based on the over-expression of PKIB or NAALADL2 in the prostate cancer, the cell proliferation function of PKIB or NAALADL2, the intracellular localization of PKIB or NAALADL2 or the interaction between PKIB and PKA-C. Also, provided are a method for treating prostate cancer by administering a double-stranded molecule against the PKIB or NAALADL2 gene. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.

    摘要翻译： 本发明通过检测PKIB或NAALADL2的过表达来检测前列腺癌，特别是激素难治性前列腺癌（HRPC）或去势抗性前列腺癌（CRPC）的方法。 还公开了基于前列腺癌中PKIB或NAALADL2的过度表达，PKIB或NAALADL2的细胞增殖功能，PKIB或NAALADL2的细胞内定位或相互作用的鉴定，鉴定用于治疗和预防前列腺癌包括HRPC的化合物的方法 PKIB和PKA-C之间。 此外，提供了通过对PKIB或NAALADL2基因施用双链分子来治疗前列腺癌的方法。 本发明还提供了包括双链分子和编码它们的载体的产物，以及可用于所提供的方法中的包含分子或载体的组合物。

    Genes and polypeptides relating to prostate cancers
    17.
    发明授权
    Genes and polypeptides relating to prostate cancers 失效
    与前列腺癌相关的基因和多肽

    公开(公告)号：US07521205B2

    公开(公告)日：2009-04-21

    申请号：US10529381

    申请日：2003-09-22

    申请人： Yusuke Nakamura ,  Toyomasa Katagiri ,  Hidewaki Nakagawa ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Toyomasa Katagiri ,  Hidewaki Nakagawa ,  Shuichi Nakatsuru

    IPC分类号： C12P21/06

    CPC分类号： C07K14/47 ,  C12Q1/6886 ,  C12Q2600/136

    摘要： The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.

    摘要翻译： 本申请提供了新型人基因MICAL2-PV，其表达在前列腺癌中显着升高。 此外，它提供由该基因编码的多肽以及由PCOTH编码的多肽，其表达也被发现在前列腺癌中升高。 由该基因编码的基因和多肽可以用于例如前列腺癌的诊断，作为用于开发针对该疾病的药物的靶分子，以及用于减轻前列腺癌的细胞生长。

    Genes and polypeptides relating to prostate cancers
    18.
    发明申请
    Genes and polypeptides relating to prostate cancers 审中-公开
    与前列腺癌相关的基因和多肽

    公开(公告)号：US20050259483A1

    公开(公告)日：2005-11-24

    申请号：US11088634

    申请日：2005-03-23

    申请人： Yusuke Nakamura ,  Toyomasa Katagiri ,  Hidewaki Nakagawa ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Toyomasa Katagiri ,  Hidewaki Nakagawa ,  Shuichi Nakatsuru

    IPC分类号： C07K14/47 ,  G11C5/00

    CPC分类号： C07K14/4748

    摘要： Objective methods for detecting and diagnosing prostate cancer (PRC) or prostatic intraepithelial neoplasia (PIN) are described herein. In one embodiment, the diagnostic method involves the determining an expression level of PRC-associated gene that discriminate between PRC or PIN and nomal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of either or both of PRC and PIN, methods of treating either or both of PRC and PIN and method of vaccinating a subject against either or both of PRC and PIN.

    摘要翻译： 本文描述了用于检测和诊断前列腺癌（PRC）或前列腺上皮内瘤变（PIN）的客观方法。 在一个实施方案中，诊断方法涉及确定区分PRC或PIN和正常细胞的PRC相关基因的表达水平。 本发明还提供筛选用于治疗PRC和PIN中的任一者或两者的治疗剂的方法，治疗PRC和PIN中的任一者或两者的方法以及针对PRC和PIN中的任一者或两者接种受试者的方法。

    SEMA5B peptides and vaccines including the same
    19.
    发明授权
    SEMA5B peptides and vaccines including the same 有权
    SEMA5B肽和疫苗包括它们

    公开(公告)号：US09187556B2

    公开(公告)日：2015-11-17

    申请号：US14118693

    申请日：2012-06-07

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    IPC分类号： C07K14/00 ,  C07K16/18 ,  C07K14/47 ,  G01N33/574 ,  A61K39/00 ,  A61K38/00

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/4703 ,  G01N33/57492 ,  G01N2333/70539

    摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。